PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Otto Kauko, Caitlin M. O'Connor, Evgeny Kulesskiy, Jaya Sangodkar, Anna Aakula, Sudeh Izadmehr, Laxman Yetukuri, Bhagwan Yadav, Artur Padzik, Teemu Daniel Laajala, Pekka Haapaniemi, Majid Momeny, Taru Varila, Michael Ohlmeyer, Tero Aittokallio, Krister Wennerberg, Goutham Narla, Jukka Westermarck

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
Artikelnummer1093
TidskriftScience translational medicine
Volym10
Utgåva450
Antal sidor12
ISSN1946-6234
DOI
StatusPublicerad - 18 jul 2018
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3111 Biomedicinska vetenskaper
  • 1182 Biokemi, cell- och molekylärbiologi

Citera det här

Kauko, Otto ; O'Connor, Caitlin M. ; Kulesskiy, Evgeny ; Sangodkar, Jaya ; Aakula, Anna ; Izadmehr, Sudeh ; Yetukuri, Laxman ; Yadav, Bhagwan ; Padzik, Artur ; Laajala, Teemu Daniel ; Haapaniemi, Pekka ; Momeny, Majid ; Varila, Taru ; Ohlmeyer, Michael ; Aittokallio, Tero ; Wennerberg, Krister ; Narla, Goutham ; Westermarck, Jukka. / PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. I: Science translational medicine. 2018 ; Vol. 10, Nr. 450.
@article{fc120ff3890b4e5eb0b1e0164f680052,
title = "PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells",
keywords = "PROTEIN PHOSPHATASE 2A, TUMOR-SUPPRESSOR, BREAST-CANCER, KINASE INHIBITORS, MYELOID-LEUKEMIA, CIP2A, MYC, SENSITIVITY, PME-1, HAPLOINSUFFICIENCY, 3111 Biomedicine, 1182 Biochemistry, cell and molecular biology",
author = "Otto Kauko and O'Connor, {Caitlin M.} and Evgeny Kulesskiy and Jaya Sangodkar and Anna Aakula and Sudeh Izadmehr and Laxman Yetukuri and Bhagwan Yadav and Artur Padzik and Laajala, {Teemu Daniel} and Pekka Haapaniemi and Majid Momeny and Taru Varila and Michael Ohlmeyer and Tero Aittokallio and Krister Wennerberg and Goutham Narla and Jukka Westermarck",
year = "2018",
month = "7",
day = "18",
doi = "10.1126/scitranslmed.aaq1093",
language = "English",
volume = "10",
journal = "Science translational medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science (AAAS)",
number = "450",

}

Kauko, O, O'Connor, CM, Kulesskiy, E, Sangodkar, J, Aakula, A, Izadmehr, S, Yetukuri, L, Yadav, B, Padzik, A, Laajala, TD, Haapaniemi, P, Momeny, M, Varila, T, Ohlmeyer, M, Aittokallio, T, Wennerberg, K, Narla, G & Westermarck, J 2018, 'PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells' Science translational medicine, vol. 10, nr. 450, 1093. https://doi.org/10.1126/scitranslmed.aaq1093

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. / Kauko, Otto; O'Connor, Caitlin M.; Kulesskiy, Evgeny; Sangodkar, Jaya; Aakula, Anna; Izadmehr, Sudeh; Yetukuri, Laxman; Yadav, Bhagwan; Padzik, Artur; Laajala, Teemu Daniel; Haapaniemi, Pekka; Momeny, Majid; Varila, Taru; Ohlmeyer, Michael; Aittokallio, Tero; Wennerberg, Krister; Narla, Goutham; Westermarck, Jukka.

I: Science translational medicine, Vol. 10, Nr. 450, 1093, 18.07.2018.

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

TY - JOUR

T1 - PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

AU - Kauko, Otto

AU - O'Connor, Caitlin M.

AU - Kulesskiy, Evgeny

AU - Sangodkar, Jaya

AU - Aakula, Anna

AU - Izadmehr, Sudeh

AU - Yetukuri, Laxman

AU - Yadav, Bhagwan

AU - Padzik, Artur

AU - Laajala, Teemu Daniel

AU - Haapaniemi, Pekka

AU - Momeny, Majid

AU - Varila, Taru

AU - Ohlmeyer, Michael

AU - Aittokallio, Tero

AU - Wennerberg, Krister

AU - Narla, Goutham

AU - Westermarck, Jukka

PY - 2018/7/18

Y1 - 2018/7/18

KW - PROTEIN PHOSPHATASE 2A

KW - TUMOR-SUPPRESSOR

KW - BREAST-CANCER

KW - KINASE INHIBITORS

KW - MYELOID-LEUKEMIA

KW - CIP2A

KW - MYC

KW - SENSITIVITY

KW - PME-1

KW - HAPLOINSUFFICIENCY

KW - 3111 Biomedicine

KW - 1182 Biochemistry, cell and molecular biology

U2 - 10.1126/scitranslmed.aaq1093

DO - 10.1126/scitranslmed.aaq1093

M3 - Article

VL - 10

JO - Science translational medicine

JF - Science translational medicine

SN - 1946-6234

IS - 450

M1 - 1093

ER -